Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 18, Issue 2, 1996, Pages 117-122

  Bezek, S ^a   Kukan, M ^b   Scasnar V ^a   Lukacsova M ^b   Trnovec, T ^b  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

Author keywords

bendamustine; distribution; liver and kidney uptake; whole body autoradiography

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LABELING; DRUG TISSUE LEVEL; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTORADIOGRAPHY; CARBON RADIOISOTOPES; INJECTIONS, INTRAVENOUS; ISOTOPE LABELING; KIDNEY; LIVER; MALE; MICE; NITROGEN MUSTARD COMPOUNDS; REFERENCE STANDARDS; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 0029903088     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Preiss, R., Sohr, R., Matthias, M., Brockmann, B., Huller, H. Pharmacokinetics of bendamustine (cytostasan) in patients. Pharmazie 1985, 40: 782-4.
2. 1H-NMR. Org Magnetic Resonance 1982, 19: 15-20.
3. 14C-cytostasan solutions and its extraction using dicarbolide of cobalt. Pharmazie 1988, 43: 176-8.
4. 14C-cytostasan solutions during preparation and storage. J Radioanal Nucl Chem 1988, 121: 489-97.
5. Amlacher, R., Weber, H., Preiss, R., Hoffmann, H. Influence of leukemia P388 on plasma concentration-time profiles of bendamustine in B6DZF1 mice. Pharmazie 1992, 47: 378-81.
6. Bezek, S., Scasnár, V., Trnovec, T., Grupe, R. Hepatobiliary elimination of bendamustin (cytostasan) in rats. Pharmazie 1991, 46: 810-1.
7. Braunlich, H., Stolze, G., Stolze, R. Renal effects of bendamustin (cytostasan) in rats. Pharmazie 1988, 43: 265-8.
8. Kramarczyk, K., Jungstand, W. Vergleichende untersuchungen zur alkylierenden reaktivitaet von IMET 3393 in blut und leberhomogenaten der Maus nach iv. applikation. Zbl Pharm 1971, 118: 1099-110.
9. Werner, W., Letsch, G., Ihn, W., Sohr, R., Preiss, R. Synthesis of a potential metabolite of the anticancer drug bendamustine (cytostasan). Pharmazie 1991, 46: 56-7.
10. Hirom, P.C., Millburn, P., Smith, R.L., Williams, R.T. Species variation in the threshold molecular weight for the biliary excretion of organic ions. Biochem J 1972, 129: 1071-9.
11. Klaassen, C.D., Watkins, J.B. Mechanism of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev 1984, 36: 1-67.
12. Groothuis, D.R., Lippitz, B.E., Fekete, I. et al. The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma. Cancer Res 1992, 52: 5590-6.
13. Genka, S., Deutsch, J., Shetty, U.H. et al. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clin Exp Metastasis 1993, 11: 131-40.
14. 14[C-ring] melphalan in the rat. Cancer Chemother Pharmacol 1982, 8: 271-6.